How to Help Your Patients Save Money on Lomustine: A Provider's Guide to Savings Programs

Lomustine (Gleostine) presents one of oncology's most challenging financial access scenarios: a clinically essential drug that is not covered by Medicare or Medicaid, priced at $600–$2,950 per dose, and available from only a single manufacturer. For oncology care teams, navigating this access barrier has become a routine part of initiating lomustine therapy. This guide provides a systematic approach to helping your patients afford lomustine.

Understanding the Financial Landscape for Lomustine

The financial picture for lomustine varies significantly by patient population:

Medicare patients: Standard Medicare Part D does not cover lomustine since 2021. Some Medicare Advantage plans may have separate formulary coverage — always check. For those without coverage, out-of-pocket cost is the full retail price.

Medicaid patients: Federal Medicaid coverage was removed when NextSource left the rebate program in 2021. Some states may still cover it using state funds — check your state's Medicaid formulary.

Commercial insurance patients: Coverage varies widely. Prior authorization is nearly always required. Some plans deny first, creating appeals work for your team.

Uninsured patients: Face the full retail price; patient assistance programs are the primary lifeline.

Patient Assistance Programs

Prescription Hope

Prescription Hope is a national advocacy program that works alongside any existing insurance to obtain medications from manufacturers at approximately $70/month per drug. It is not an insurance plan or coupon — it is an enrollment-based advocacy service.

Key points for providers:

Works regardless of insurance status (with or without coverage)

Enrollment process takes time — initiate early, before the first dose is needed

Approximately $70/month per medication to the patient, regardless of retail price

Website: prescriptionhope.com

NeedyMeds Disease-Specific PAPs

NeedyMeds.org maintains an up-to-date database of manufacturer and foundation patient assistance programs. Your care team should search for lomustine on NeedyMeds to identify current available programs, as new programs may emerge or existing ones may change terms.

Prescription Discount Programs for Patients Without Insurance Coverage

For patients with commercial insurance that doesn't cover lomustine, or for uninsured patients who cannot qualify for a PAP, prescription discount cards provide the next level of savings:

GoodRx: Generic lomustine from approximately $672; brand Gleostine approximately $2,651 at participating pharmacies. Printable coupons at goodrx.com

SingleCare: Gleostine 10 mg (5 capsules) potentially reduced to $215.75 at CVS, Walgreens, Walmart, and Kroger

WellRx: Competitive pricing at select pharmacies including HEB and Kroger

Important: Discount cards work in place of insurance. They cannot be combined with insurance coverage. Help patients compare whether their insurance copay or the GoodRx cash price is lower.

Cancer Foundation Financial Assistance

Several cancer-focused foundations maintain financial assistance funds that may help brain tumor and lymphoma patients with chemotherapy costs:

National Brain Tumor Society (NBTS): nbts.org — provides navigation resources and may have access to financial assistance programs

Leukemia & Lymphoma Society (LLS): lls.org — financial assistance program for blood cancer patients

HealthWell Foundation: healthwellfoundation.org — co-pay assistance for underinsured patients when funding is available

Patient Advocate Foundation: patientadvocate.org — case management and financial assistance navigation

Commercial Insurance: Prior Authorization and Appeals Protocol

For commercially insured patients, a proactive PA approach is essential:

Submit early: File the PA request at least 2 weeks before cycle 1

Include clinical documentation: Diagnosis codes, pathology, MGMT status, treatment history, and rationale for lomustine vs. available alternatives

Peer-to-peer on denial: Request immediate peer-to-peer review; oncologist discusses the clinical case with the plan's medical director

Appeal with NCCN guidelines: NCCN guidelines list lomustine as standard of care for recurrent GBM and certain gliomas — cite these in appeals

External review: Patients have the right to an independent external review of denied PA requests in most states

Integrating Financial Navigation Into Your Workflow

Best-practice recommendations for oncology practices:

Assign a dedicated financial navigator or social worker to every new patient being initiated on lomustine

Build a standard intake checklist that screens for insurance type, income level, and awareness of assistance programs at the first visit

Build PAP enrollment into your pre-treatment protocol — don't wait until the patient reports they can't afford the drug to start this process

Re-screen each cycle — patient's financial situation and insurance status can change during treatment

Once financial access is secured, help your patients locate the drug physically using medfinder for providers. Also see our clinical guide on lomustine shortage and access challenges for prescribers.